文献速递妇科

新辅助腹腔热灌注化疗对晚期高级别浆液性卵巢癌患者化疗反应评分及复发的影响:一项多中心回顾性队列研究

Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence in high-grade serous ovarian cancer patients with advanced disease: A multicentre retrospective cohort study.
PubMed 文献 · BJOG · 2022-01-01

这项多中心回顾性队列研究纳入2012至2020年间接受新辅助化疗及间歇性减瘤术的卵巢癌患者127例,其中46例接受新辅助腹腔热灌注化疗(NHIPEC)联合静脉新辅助化疗(IV NACT)。结果显示NHIPEC联合IV NACT与CRS 3可能性增加独立相关(p=0.033),中位无进展生存期(PFS)22个月 vs 16个月(p<0.001),总生存期(OS)组间无显著差异(p=0.062)。

要点

  • NHIPEC联合IV NACT与CRS 3可能性增加独立相关(p=0.033)。
  • NHIPEC联合IV NACT组中位PFS 22个月,IV NACT单用组16个月(p<0.001)。
  • 两组OS无显著差异(p=0.062),但观察到有利于NHIPEC的趋势。

核心结论

  • 与单用IV NACT相比,NHIPEC联合IV NACT改善了肿瘤反应并延长了PFS,且未增加不良事件风险或影响IDS的手术复杂性。

研究设计与样本

  • 多中心回顾性队列研究,纳入2012至2020年间接受NACT-间歇性减瘤术(IDS)的卵巢癌患者127例,其中46例接受NHIPEC联合IV NACT。

主要发现

  • NHIPEC的加入与CRS 3可能性增加独立相关(p=0.033)。
  • NHIPEC联合IV NACT组中位PFS为22个月,IV NACT单用组为16个月(p<0.001)。
  • NHIPEC的使用被确定为PFS的独立预测因素(p<0.0001)。
  • 两组OS无显著差异(p=0.062),但观察到有利于NHIPEC的趋势。
  • 两组3-4级不良事件发生率和IDS手术复杂性评分相似。

关键数值与推荐

  • 肿瘤反应采用化疗反应评分(CRS)系统评估,主要结局指标为CRS 3、PFS和OS。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether the combination of neoadjuvant hyperthermic intraperitoneal chemotherapy (NHIPEC) plus intravenous neoadjuvant chemotherapy (IV NACT) has superior efficacy to IV NACT alone. DESIGN: Retrospective cohort study. SETTING: Two tertiary referral university hospitals. POPULATION: Patients with ovarian cancer who received NACT-interval debulking surgery (IDS) between 2012 and 2020. METHODS: The tumour response to NACT was evaluated with the chemotherapy response score (CRS) system. Survival outcomes were compared. MAIN OUTCOME MEASURES: CRS 3, progression-free survival (PFS), and overall survival (OS). RESULTS: In total, 127 patients were included, and 46 received NHIPEC plus IV NACT. The addition of NHIPEC was independently associated with an increased likelihood of CRS 3 (p = 0.033). Patients who received NHIPEC + IV NACT had significantly improved PFS compared with those who received IV NACT alone (median PFS: 22 versus 16 months, p < 0.001). The use of NHIPEC was identified as an independent predictor of PFS (p < 0.0001). OS did not differ significantly between treatment groups (p = 0.062), although a trend favouring NHIPEC was noted. Incidence of grade 3-4 adverse events and the surgical complexity score of IDS were similar between the two groups. CONCLUSIONS: Compared with IV NACT alone, the combination of NHIPEC and IV NACT resulted in improved tumour response and longer PFS. The addition of NHIPEC did not increase the risk of adverse effects or affect the complexity of IDS.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Wu MF, Liang JX, Li H, et al. Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence in high-grade serous ovarian cancer patients with advanced disease: A multicentre retrospective cohort study. BJOG. 2022. PMID: 36485072. doi:10.1111/1471-0528.17323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。